Applied BioCode (6598) - Net Assets
Based on the latest financial reports, Applied BioCode (6598) has net assets worth NT$687.57 Million TWD (≈ $21.66 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.03 Billion ≈ $32.48 Million USD) and total liabilities (NT$343.23 Million ≈ $10.81 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore how large is Applied BioCode's balance sheet for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$687.57 Million |
| % of Total Assets | 66.7% |
| Annual Growth Rate | 11.31% |
| 5-Year Change | -19.15% |
| 10-Year Change | 225.11% |
| Growth Volatility | 45.48 |
Applied BioCode - Net Assets Trend (2012–2024)
This chart illustrates how Applied BioCode's net assets have evolved over time, based on quarterly financial data. Check Applied BioCode tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Applied BioCode (2012–2024)
The table below shows the annual net assets of Applied BioCode from 2012 to 2024. For live valuation and market cap data, see 6598 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$878.83 Million ≈ $27.69 Million |
+32.96% |
| 2023-12-31 | NT$660.99 Million ≈ $20.82 Million |
-19.00% |
| 2022-12-31 | NT$816.07 Million ≈ $25.71 Million |
-9.62% |
| 2021-12-31 | NT$902.96 Million ≈ $28.45 Million |
-16.93% |
| 2020-12-31 | NT$1.09 Billion ≈ $34.25 Million |
+104.84% |
| 2019-12-31 | NT$530.65 Million ≈ $16.72 Million |
+22.63% |
| 2018-12-31 | NT$432.73 Million ≈ $13.63 Million |
+56.49% |
| 2017-12-31 | NT$276.52 Million ≈ $8.71 Million |
-35.33% |
| 2016-12-31 | NT$427.60 Million ≈ $13.47 Million |
+58.18% |
| 2015-12-31 | NT$270.32 Million ≈ $8.52 Million |
-14.37% |
| 2014-12-31 | NT$315.69 Million ≈ $9.95 Million |
+84.69% |
| 2013-12-31 | NT$170.93 Million ≈ $5.39 Million |
-29.66% |
| 2012-12-31 | NT$243.00 Million ≈ $7.66 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Applied BioCode's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4544000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$1.03 Billion | 116.96% |
| Other Comprehensive Income | NT$67.56 Million | 7.69% |
| Other Components | NT$237.36 Million | 27.01% |
| Total Equity | NT$878.83 Million | 100.00% |
Applied BioCode Competitors by Market Cap
The table below lists competitors of Applied BioCode ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Companhia Estadual de Distribuição de Energia Elétrica
SA:CEED3
|
$97.53 Million |
|
J Sainsbury PLC
LSE:SBRY
|
$97.54 Million |
|
WW Holding Inc
TW:8442
|
$97.60 Million |
|
Matrimony.Com Limited
NSE:MATRIMONY
|
$97.69 Million |
|
Samwha Electri
KO:009470
|
$97.49 Million |
|
Swelect Energy Systems Limited
NSE:SWELECTES
|
$97.43 Million |
|
Pudumjee Paper Products Limited
NSE:PDMJEPAPER
|
$97.41 Million |
|
Leofoo Development Co Ltd
TW:2705
|
$97.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Applied BioCode's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 660,990,000 to 878,830,000, a change of 217,840,000 (33.0%).
- Net loss of 260,807,000 reduced equity.
- New share issuances of 441,183,000 increased equity.
- Other comprehensive income increased equity by 34,416,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-260.81 Million | -29.68% |
| Share Issuances | NT$441.18 Million | +50.2% |
| Other Comprehensive Income | NT$34.42 Million | +3.92% |
| Other Changes | NT$3.05 Million | +0.35% |
| Total Change | NT$- | 32.96% |
Book Value vs Market Value Analysis
This analysis compares Applied BioCode's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3.81x to 3.10x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | NT$7.91 | NT$30.10 | x |
| 2014-12-31 | NT$13.22 | NT$30.10 | x |
| 2015-12-31 | NT$9.29 | NT$30.10 | x |
| 2016-12-31 | NT$9.80 | NT$30.10 | x |
| 2017-12-31 | NT$5.93 | NT$30.10 | x |
| 2018-12-31 | NT$8.17 | NT$30.10 | x |
| 2019-12-31 | NT$8.26 | NT$30.10 | x |
| 2020-12-31 | NT$14.01 | NT$30.10 | x |
| 2021-12-31 | NT$11.05 | NT$30.10 | x |
| 2022-12-31 | NT$9.98 | NT$30.10 | x |
| 2023-12-31 | NT$8.09 | NT$30.10 | x |
| 2024-12-31 | NT$9.70 | NT$30.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Applied BioCode utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -76.02%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.38x
- Recent ROE (-29.68%) is above the historical average (-41.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -121.70% | -781.47% | 0.14x | 1.14x | NT$-225.11 Million |
| 2014 | -22.55% | -468.64% | 0.04x | 1.12x | NT$-102.74 Million |
| 2015 | -7.87% | -91.45% | 0.07x | 1.15x | NT$-48.29 Million |
| 2016 | -31.78% | -1155.41% | 0.02x | 1.12x | NT$-178.64 Million |
| 2017 | -95.28% | -984.68% | 0.08x | 1.22x | NT$-291.11 Million |
| 2018 | -62.00% | -722.32% | 0.07x | 1.19x | NT$-311.58 Million |
| 2019 | -52.78% | -267.52% | 0.15x | 1.35x | NT$-333.14 Million |
| 2020 | -9.52% | -34.61% | 0.24x | 1.13x | NT$-212.20 Million |
| 2021 | -18.30% | -51.63% | 0.31x | 1.13x | NT$-255.49 Million |
| 2022 | -22.64% | -47.33% | 0.32x | 1.49x | NT$-266.34 Million |
| 2023 | -24.84% | -41.55% | 0.40x | 1.50x | NT$-230.30 Million |
| 2024 | -29.68% | -76.02% | 0.28x | 1.38x | NT$-348.69 Million |
Industry Comparison
This section compares Applied BioCode's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,408,583,400
- Average return on equity (ROE) among peers: 9.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Applied BioCode (6598) | NT$687.57 Million | -121.70% | 0.50x | $97.49 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $182.35 Million |
| Radiant Innovation (3373) | $793.80 Million | -7.61% | 0.09x | $24.15 Million |
| Wellell Inc (4106) | $1.67 Billion | 10.10% | 0.50x | $75.35 Million |
| Rossmax International Ltd (4121) | $1.94 Billion | 8.76% | 1.05x | $33.63 Million |
| United Orthopedic (4129) | $2.22 Billion | 5.87% | 0.94x | $253.70 Million |
| Dynamic Medical Technologies (4138) | $1.70 Billion | 12.34% | 0.81x | $64.28 Million |
| Ok Biotech Co Ltd (4155) | $950.15 Million | 11.68% | 0.52x | $64.02 Million |
| Bioptik Technology (4161) | $811.73 Million | 3.25% | 0.98x | $42.21 Million |
| AViTA Corporation (4735) | $996.01 Million | 9.36% | 0.36x | $37.00 Million |
| TAIDOC TECHNOLOGY CORP (4736) | $9.99 Billion | 33.85% | 0.29x | $380.72 Million |
About Applied BioCode
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target us… Read more